Skip to main content
Journal cover image

IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).

Publication ,  Journal Article
Pachynski, RK; Morishima, C; Szmulewitz, R; Harshman, L; Appleman, L; Monk, P; Bitting, RL; Kucuk, O; Millard, F; Seigne, JD; Fling, SP ...
Published in: J Immunother Cancer
August 2021

BACKGROUND: Sipuleucel-T (sip-T) is a Food and Drug Administration (FDA)-approved autologous cellular immunotherapy for metastatic castration-resistant prostate cancer (mCRPC). We hypothesized that combining sip-T with interleukin (IL)-7, a homeostatic cytokine that enhances both B and T cell development and proliferation, would augment and prolong antigen-specific immune responses against both PA2024 (the immunogen for sip-T) and prostatic acid phosphatase (PAP). METHODS: Fifty-four patients with mCRPC treated with sip-T were subsequently enrolled and randomized 1:1 into observation (n=26) or IL-7 (n=28) arms of a phase II clinical trial (NCT01881867). Recombinant human (rh) IL-7 (CYT107) was given weekly×4. Immune responses were evaluated using flow cytometry, mass cytometry (CyTOF), interferon (IFN)-γ ELISpot, 3H-thymidine incorporation, and ELISA. RESULTS: Treatment with rhIL-7 was well tolerated. For the rhIL-7-treated, but not observation group, statistically significant lymphocyte subset expansion was found, with 2.3-2.6-fold increases in CD4+T, CD8+T, and CD56bright NK cells at week 6 compared with baseline. No significant differences in PA2024 or PAP-specific T cell responses measured by IFN-γ ELISpot assay were found between rhIL-7 and observation groups. However, antigen-specific T cell proliferative responses and humoral IgG and IgG/IgM responses significantly increased over time in the rhIL-7-treated group only. CyTOF analyses revealed pleiotropic effects of rhIL-7 on lymphocyte subsets, including increases in CD137 and intracellular IL-2 and IFN-γ expression. While not powered to detect clinical outcomes, we found that 31% of patients in the rhIL-7 group had prostate specific antigen (PSA) doubling times of >6 months, compared with 14% in the observation group. CONCLUSIONS: Treatment with rhIL-7 led to a significant expansion of CD4+ and CD8+ T cells, and CD56bright natural killer (NK) cells compared with observation after treatment with sip-T. The rhIL-7 treatment also led to improved antigen-specific humoral and T cell proliferative responses over time as well as to increased expression of activation markers and beneficial cytokines. This is the first study to evaluate the use of rhIL-7 after sip-T in patients with mCRPC and demonstrates encouraging results for combination approaches to augment beneficial immune responses.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

August 2021

Volume

9

Issue

8

Location

England

Related Subject Headings

  • Tissue Extracts
  • Recombinant Proteins
  • Prostatic Neoplasms, Castration-Resistant
  • Prospective Studies
  • Neutrophils
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lymphocytes
  • Lymphocyte Activation
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Pachynski, R. K., Morishima, C., Szmulewitz, R., Harshman, L., Appleman, L., Monk, P., … Fong, L. (2021). IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer, 9(8). https://doi.org/10.1136/jitc-2021-002903
Pachynski, Russell K., Chihiro Morishima, Russell Szmulewitz, Lauren Harshman, Leonard Appleman, Paul Monk, Rhonda L. Bitting, et al. “IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).J Immunother Cancer 9, no. 8 (August 2021). https://doi.org/10.1136/jitc-2021-002903.
Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, et al. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 Aug;9(8).
Pachynski, Russell K., et al. “IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC).J Immunother Cancer, vol. 9, no. 8, Aug. 2021. Pubmed, doi:10.1136/jitc-2021-002903.
Pachynski RK, Morishima C, Szmulewitz R, Harshman L, Appleman L, Monk P, Bitting RL, Kucuk O, Millard F, Seigne JD, Fling SP, Maecker HT, Duault C, Ramchurren N, Hess B, D’Amico L, Lacroix A, Kaiser JC, Morre M, Grégoire A, Cheever M, Yu EY, Fong L. IL-7 expands lymphocyte populations and enhances immune responses to sipuleucel-T in patients with metastatic castration-resistant prostate cancer (mCRPC). J Immunother Cancer. 2021 Aug;9(8).
Journal cover image

Published In

J Immunother Cancer

DOI

EISSN

2051-1426

Publication Date

August 2021

Volume

9

Issue

8

Location

England

Related Subject Headings

  • Tissue Extracts
  • Recombinant Proteins
  • Prostatic Neoplasms, Castration-Resistant
  • Prospective Studies
  • Neutrophils
  • Neoplasm Metastasis
  • Middle Aged
  • Male
  • Lymphocytes
  • Lymphocyte Activation